SIGNIA: An innovative drug discovery platform for rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing.

Informations projet

SIGNIA

N° de convention de subvention: 826722

DOI

10.3030/826722

Projet clôturé

Date de signature de la CE 16 Juillet 2018

Date de début 1 Août 2018

Date de fin 30 Novembre 2018

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

SIGNIA THERAPEUTICS
France

Periodic Reporting for period 1 - SIGNIA (SIGNIA: An innovative drug discovery platform for rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing.)

Période du rapport: 2018-08-01 au 2018-11-30

Résumé du contexte et des objectifs généraux du projet

The Final Report resumes the work done by Signia during Phase 1 execution in order to verify the feasibility of Signia project to optimize our disruptive drug repurposing platform and release it to the market. We planned to improve its screening capability and to in-house develop customized nebulization devices, to later undergo clinical validation. We made an assessment of all the investment required to complete the project, for which we will pursue financing support of circa €2.5M from the EC scheme of SMEi Phase 2. After an assessment of Signia´s financial analysis, we have evaluated the potential of Signia to generate profit (€31.6M of revenue and €22.5M profit) and new employment (+14 new job positions). We have already received positive proofs of interest from our key stakeholders: public research centres (Centre Hospitalier Universitaire de Québec, Centre d´Etude des Pathologies Respiratoires INSERM UMR 1100 at Université de Tours or Lille University Hospital) and private pharma and biotech companies (Sanofi, Cynbiose or Evotec).
Finally, we concluded to continue with Signia project, motivated by our feasibility study which confirms the uniqueness and competitiveness of our innovation.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

TECHNICAL FEASIBILITY, including: product specification and technology definition; analysis of validation procedures; detailed technical plan to increase TRL to 9; analysis of risks and design of a mitigation and contingency plan.
COMMERCIAL FEASIBILITY, including: market analysis; end-user´s segmentation; main competitors; definition of commercial strategy; SoA and FtO analysis; business model; commercialization and dissemination plan, including IPR strategy.
FINANCIAL FEASIBILITY, including: in-depth cost analysis to evaluate our capacity to take the innovation; business projections for the first five years after Signia market launch in a conservative sales scenario.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Signia will be the first drug discovery platform to identify new antimicrobial application among available drugs and pharmaceutical resources, avoiding the impact of intrinsic microbe mutability by targeting the infected cell, making possible to identify a broad spectrum of antimicrobials by targeting common features of an infected cell, and accelerating drug discovery process in terms of cost, regulations and time-to-market. It will allow a huge growth for our company (+€31.6M revenue and +14 new employees at the 4th year of commercialization).

image-1.png